VCs Have Money to Invest in the Right Deal
Just about the time you begin to wonder if VCs are making any investments at all comes word that VCs want to invest in the obesity space (Glasner): Thythm Pharmaceuticals go $21 million; GI Gynamics go $15 million; Satiety got $25 million; Elixir Pharmaceuticals got $12 million; ValenTX got $22 million. All these investments have to do with treatments for obesity. Rush out to develop a new treatment yourself? It is probably too late, unless you really do have a disruptive methodology.
Reference
Glasner, Joanna. Rise in obesity makes VCs hungry for startups. Reuters. 25 Mar 2010. http://www.reuters.com/article/idUSTRE62O3SO20100325?type=smallBusinessNews